ABSTRACT: Joint pathology and degeneration is a significant cause of pain. The synovial membrane plays an important role in maintenance of the joint, contributes to the pathology of many arthropathies and may be adversely affected in joint disease. Improving knowledge of the receptors present within the synovium will aid in a better understanding of joint pathology and the development of new treatments for diseases such as osteoarthritis and rheumatoid arthritis. Knowledge of the location and function of synovial membrane receptors (both in healthy and diseased synovium) may provide important targets in the treatment of various arthropathies.
Arthropathies can be a significant source of pain and finding new therapeutic treatments to alleviate that pain is paramount. The synovial membrane plays an important role in maintenance of the joint, contributes to the pathology of many arthropathies 1 and may be adversely affected in joint disease. 2 The synovial membrane consists of two layers, the intima and the subintima, with a small amount of hyaluronan between layers. The intima is relatively acellular but consists of two types of synoviocytes, type A, which is of macrophage or monocyte cell lines and type B, which is a fibroblast. The subintima is composed of blood and lymphatic vessels 3 and loose connective tissue and merges with the outer layer of the joint capsule. 1 The synoviocytes are important in producing synovial fluid for cartilage lubrication, chondrocyte nutrition, and control of synovial fluid volume through the production of hyaluronic acid, 1, 3 They may also play an important role in joint pathology by increasing joint friction, regulation of inflammation, and fibrosis 1 and regulation of synovial immune function. 3 Synovial inflammation is evident in osteoarthritis (OA) and inflamed synoviocytes may react to cartilage degradation enzymes and result in the release of cytokines and matrix metalloproteinases. 2, 4 Knowledge of the receptors present within the synovium, may aid in the understanding of joint disease and lead to development of new treatments for arthropathies. Extensive research has determined many of the important receptors responsible for normal synovial membrane function and those important in modulating disease, particularly inflammatory arthropathies. The presence and function of synovial membrane receptors in both normal and diseased synovium are an important target in the prevention and treatment of arthropathies and will be discussed in this review.
RECEPTOR STRUCTURE AND FUNCTION

Opioid Receptors
Endogenous opioids, enkephalin, endorphins, and dynorphin, are primarily involved in antinociception, 5 although nociceptin can display either pro-or antinociceptive characteristics. 6 The opioid receptors are G-protein coupled receptors and include the m, k, d, and nociceptin receptor types. 7 Synovial opioid receptors have been demonstrated in humans, [8] [9] [10] [11] dogs, 12 rats, 13 and horses. 14,15 m-opioid receptors have been detected in the synovium of normal rats 13 and humans with OA, rheumatoid arthritis (RA), and joint trauma, 9 while k-and d-receptors have been demonstrated in the RA and OA synovium. 10 While opioid receptors are known to be important in analgesia, they may also play a role in inflammation as outlined in Table 1 . The density of these receptors is significantly increased in inflamed joints 12, 15 compared to healthy joints. 10, 16 However, receptor downregulation may occur in chronic arthropathies. 8, 10 In patients with chronic OA, the expression of d-and k-opioid receptors is significantly reduced compared to normal expression. Toll-like receptors  TLR2  IL-1b, IL-6, MMP-3, TNF-a release  TLR3  IL-6,MMP-3 release  TLR4  IL-1b, IL-6, MMP-3, TNF-a release  TLR5  IL-6,MMP-3 release  TLR7  Cartilage degradation  Increases IL-6 and IL- 21 While glucocorticoids are often used as anti-inflammatories and analgesics, there seems to be no correlation between the density of glucocorticoid receptors and pain.
18
Glutamate Receptors
Glutamate is an excitatory neurotransmitter within the central nervous system, 22 particularly the dorsal root ganglia of the spinal cord 23 and is important in nociception. There are two main types of glutamate receptors, metabotropic (mGluR) and ionotropic (iGluR). The iGluRs include NMDA, AMPA, and kainate. 24 Increased synovial fluid glutamate has been detected in patients with arthropathies, 25 leading to the evaluation of glutamate receptors in the synovium.
The NMDA receptor is important in nociceptive modulation 26 and the development of central sensitization. Activation results in excitation of sensory neurons or secretion of inflammatory peptides.
27 NMDA receptors are comprised of two NR1 subunits and any combination of two NR2 subunits, NR2A-D. 27, 28 There is evidence for the presence of the NR2D subunit in the healthy rat synovium 29 and both the NR1 and NR2 subunits in human synoviocytes. 27 In rat synovium, iGluR3 and kainate2 mRNA was detected but no other subtypes were detected. 29 In a different study, kainate1 and iGluR2 receptors were identified in both rat and human synovium.
30
Transient Receptor Potential Channels The transient receptor potential (TRP) receptors are ion channels that detect and transduce noxious and non-noxious thermal and chemical stimuli. Since they act as nociceptors, they may also be involved in pathological pain states. 31 There are seven members of this family including TRP vanilloid (TRPV), TRP ankyrin (TRPA), TRP melastatin (TRPM), and TRP canonical (TRPC). TRPV1 detects noxious thermal signals (>42˚C). 32 Activation of TRPV1 has resulted in induction of the formation of the metabolites of unstable reactive oxygen species, 33 and increased the expression of cyclooxygenase-2, 34 TNFa, and the chemokine RANTES.
33,34 TRPV1 receptors were detected on synovial membranes of human synoviocytes 35 and in the synovial membrane of rat temporomandibular joints.
36
TRPV3 and TRPV4 have both been detected in healthy synoviocytes. 35 Due to the lack of receptor activation in the TRPV3 temperature range, 37 it is likely that TRPV4 is the predominant "moderate" temperature receptor in the synovium. TRPM3, 7, and 8 have also been detected in the synovium. 32, 38, 39 TRPM3 is primarily activated by hypotonic cellular swelling 38 and TRPM8 responds to cool temperatures (less than 25˚C). 39 The expression of functional TRMP3 has been detected in healthy rabbit synovium. TRPM7 was detected in the synovium of rats with adjuvant-induced arthritis and healthy rats with higher expression in the arthritic synovium.
40
TRPA1 is a cold sensing ion channel that has been detected on nociceptors and may play a role in hyperalgesia 41 and cold hypersensitivity. 42 TRPA1 was detected in healthy and adjuvant-induced arthritis mouse synovial membranes 43 and appears to mediate increases in blood flow to arthritic joints in response to cold exposure. 43 Finally TRPC5, which is activated by thioredoxin, has been found in like fibroblast-like synoviocytes from RA patients. 44 ,45 TRCP5 has been associated with a decrease in synovial fluid cytokines, in mice. 45 Despite their synovial localization, the function of the TRP receptors in both synovial thermal nociception and inflammation is not well defined.
Chemokines
Chemokines are small, secreted molecules that are important in the promotion of inflammation, angiogenesis, chemotaxis, and cartilage degeneration. Chemokines have been discovered within the synovial fluid from humans with RA, OA, and joint trauma [49] [50] [51] [52] and in healthy horses and horses with osteochondral injury. 53 In rats with adjuvant-induced arthritis 54 and humans, 48 CCR1, CCR4, CCR5, 48, 54 and CCR2 48 were identified in synovial tissue, with higher expression of CCR in OA joints compared to healthy joints. 55 CXCR1, CXCR2, and CXCR4 have been detected in the synovium of rats 48 and CCR9 in RA and OA synovial tissue.
47
CCR1, CCR2, and CCR5 expression in the synovium has been positively correlated with the peak of clinical inflammation and is associated with macrophage and lymphocyte infiltration.
46 Synovial CCR9 has also been implicated in mononuclear cell infiltration, 47 while CXCR1 and CXCR2 are involved in neutrophil chemotaxis. 56 Additionally, CCL2 has been shown to increase monocyte adhesion to synoviocytes via CCR2 activation. 46 Blockade of CCR9 decreased matrix metalloproteinase-3 related cartilage degradation.
CXCR3 may mediate fibroblast invasion, which may be important in the development of arthropathies. 57, 58 Interleukin Receptors Interleukins (IL), a member of the cytokine family, are important in modulation of the inflammatory response. They have been found in synovial fluid from patients with arthropathies. 59 Members of the IL-1 family of receptors that have been detected in the synovium include IL-1R and IL-18R. 60 Receptors belonging to the IL-17R family have been detected in the synovial intimal lining in patients with RA, OA, 61, 62 psoriatic arthritis, and traumatic arthropathies. 62 In RA synovium, a correlation between IL-1R expression and IL-6, IL-8, PGE 2 , and vascular endothelial growth factor release may point to a role for IL-1R in cytokine release. 63 
IL-18R
64,65 and IL-21R 66 have been detected in the synovial membrane of patients with RA. While some OA tissue but not all expressed IL-18R 64 and none expressed IL-21R. 66 These receptors and chemokines may be important not only in inflammation but also in synovial hyperplasia, as IL-22 increased synoviocyte proliferation in both RA and OA tissue. 67 
Prostanoid Receptors
Prostanoids are important in inflammation particularly in mediating pain, swelling, vasodilation, and vascular permeability. The prostanoid receptors are G-protein coupled and there are four subtypes of PGE receptors, EP1-4. 68 In humans, synovial localization of EP2 and EP4 was confirmed, while EP1 and EP3 were not detected. 69 In rats with adjuvant-induced arthritis, EP2, 70 EP3B, 70, 71 and EP4 70, 72 are expressed. 70, 71 In rat synovial cells, EP2 and EP4 agonists attenuated IL-1 induced IL-6 expression and release, 70 while EP3 selective agonists have resulted in increased IL-6 production. 71 In human OA and rat synoviocytes these agonists decreased IL-1 induced monocyte chemoattractant protein-1 production. 73 Finally, blockade of EP4 resulted in a significant reduction of arthritis scores in mice 74 and activation of EP2 in rabbits has been associated with increased type II collagen and cartilage regeneration. 75 Prostacyclin, another prostanoid, is systemically important in platelet activation and vasodilation. Both prostacyclin and its receptor are constitutively expressed by OA synoviocytes. 76 Inhibition of the prostacyclin receptor in the mouse synovium resulted in significantly lower subjective arthritis scores, less inflammatory cell infiltration, less bone and cartilage destruction, and decreased IL-1b and IL-6 production. 74 Histamine Systemic histamine is functionally important for allergic reactions, inflammation, and gastric acid secretion. 77 The effects of histamine are mediated through four distinct G-protein coupled receptors, [78] [79] [80] 78, 80 Histamine has resulted in increased expression of IL-1b, IL-6, and IL-8 in synovial cell cultures. 79 Systemic blockade of H 4 R attenuated the release of synovial TNF-a in response to intra-articular administration of lipopolysaccharide. 81 A negative correlation has been identified between serum matrix metalloproteinase-3 concentration and synovial H 4 R expression, 80 which may represent a negative feedback loop in synovial inflammation.
Bradykinin
Bradykinin is a mediator of inflammation that can cause smooth contraction, vasodilation, increased vascular permeability, increased leukocyte migration, and induction of pain. 82 It is also up-regulated in the presence of inflammation. 83 Bradykinin binds to two different receptors inducible B 1 and constitutive B 2 .
84
As early as 1992, bradykinin receptors were detected in synovial joints. 82, 83 The B 2 receptor was found in healthy and inflamed synovial tissue in rats 85 and the synovial lining of human OA tissue.
84 B 1 expression was only present in some rats after induction of arthritis 85 and none of the human OA samples.
Patient selection may have prevented the detection of B 1 receptors as the majority of patients had chronic disease and B 1 is likely induced during acute inflammation.
In rabbit knees activation of B 1 was associated with an increase in synovial blood flow within the inflamed joint.
86 Through the actions of B 2 , bradykinin can increase the production of IL-1 87,88 and IL-8 in the synovium, independent of cyclooxygenase. 87 Finally, B 2 activation has been associated with local endothelial cell proliferation in mildly inflamed joints. 96 The role of these receptors in the synovium, to the authors' knowledge, has not been examined.
Serotonin
Serotonin, 5-HT, has been implicated in spinal mediated anti-nociception through excitation of inhibitory interneurons within the spinal cord. 5-HT may also be involved in spinal facilitation of descending nociceptive signals, making it both pro-and anti-nociceptive. There are several 5-HT receptor subtypes, 1 A-F , 2 A-C , 3,4,5 A,B , 6,7. All of which are metabotropic, with the exception of 5-HT 3 , which is ionotropic. 5 A study in rats with adjuvant-induced arthritis, identified elevated levels of synovial fluid 5-HT in inflamed compared to healthy joints. 99 The effect on PGE 2 release was blocked by the 5-HT 2 antagonist, ketanserin. 101 
Purinergic Receptors
The purine receptors are divided into the P1, P2, and adenosine types. The adenosine receptor is comprised of four distinct subtypes Adenosine 1 , Adenosine 2A , Adenosine 2B , and Adenosine 3 , which are all G-protein coupled and are anti-inflammatory. The main ligand for adenosine receptors is adenosine. [102] [103] [104] The P2X type of P2 receptors is a ligand-gated ion channel 104 and is further divided into seven subtypes, P2X 1-7. Signaling is mediated by binding of ATP 105 and can result in either pro-or anti-inflammatory actions. Adenosine has been identified in the synovial fluid from humans with OA and RA. 106 OA synoviocytes expressed Adenosine 1 , Adenosine 2A , Adenosine 2B , and Adenosine 3 receptors with higher expression of Adenosine 2A and Adenosine 3 . 104 In bovine synoviocytes, Adenosine 1 , Adenosine 2A , Adenosine 2B , and Adenosine 3 receptors were also identified. 102, 103 Adenosine and its receptors are associated with decreases in inflammation [102] [103] [104] and decreased cartilage destruction. 107, 108 Lipopolysaccharide induced release of PGE 2 is inhibited by administration of Adenosine 1 , Adenosine 2A , Adenosine 2B , and Adenosine 3 agonists in bovine synoviocytes, 103 while administration of Adenosine 2A and Adenosine 3 agonists resulted in decreased release of IL-8 and TNF-a in response to lipopolysaccharide in end stage OA synovium.
104
P2 receptors have also been identified in synovial tissue. 104, 105, 109 In human OA synoviocytes, mRNA expression of P2X 1-7 was seen, with higher expression of P2X 1 , P2X 3 , and P2X 7 .
104 P2X 1 resulted in decreased production and release of TNF-a in the OA synovium, 104 while both P2X 3 104 and P2X 4 agonists increase the release of TNF-a. P2X 4 activation also increases IL-1, IL-6, IL-17 110 and brain derived neurotrophic factor, while inhibition is associated with decreased inflammatory cell infiltration and synovial hyperplasia.
40 P2X 7 agonists also increase synovial IL-6 production. 105 Lipoxin Lipoxins are lipid inflammatory mediators, formed from arachadonic acid, that are found during the resolution of inflammation. 111 ALX is the receptor for lipoxin A4; however, serum amyloid A also appears to be an important ligand for this G-protein coupled receptor. 111, 112 ALX expression has been identified in human synoviocytes, and the expression is increased in the presence of IL-1b. 112 Lipoxin A 4 is important in the inhibition of neutrophil activation and can alter the release of proinflammatory cytokines. 111, 113 Synovial lipoxin A 4 is associated with the release of IL-6, IL-8, and matrix metalloproteinase-3 in response to IL-1b. 113 Finally in human synoviocytes, ALX ligands can decrease serum amyloid A and inflammatory cell chemotaxis and induce IL-8 release. 112 
Non-Neuronal Cholinergic System
Acetylcholine is a neurotransmitter that binds to two different cholinergic receptors, nicotinic, and muscarinic. Nicotinic receptors are inotropic and are typically sodium channels. Degradation of acetylcholine is due to activity of acetylcholinesterase. The nicotinic receptors, particularly the a7 receptor (a7R), modulate inflammation by decreasing the synthesis of cytokines 114 and are present in a variety of tissues such as immune and inflammatory cells. 115 The a2, a3, a4, a5, a6, a7, a9, and a10 subunits of the nicotinic receptor were identified in OA synovium. 116 The a7R has also been noted in the synovium from healthy volunteers. 117 In the synovium, acetylcholine and pyridostigmine, an acetylcholinesterase inhibitor, decrease IL-1 induced IL-6 release. 115 Epidermal Growth Factor Receptor Epidermal growth factor receptor (EGFR) is a member of the family of receptor tyrosine kinases. This family of receptors plays a major role in cellular proliferation and cell maintenance. The ligands for EGFR are transforming growth factor-a, amphiregulin, and EGF. 118 Several ligands for EGFR, particularly amphiregulin, have been identified in synovial tissue of RA and OA patients, with higher expression in SYNOVIAL MEMBRANE RECEPTORS AS THERAPEUTIC TARGETS RA. 119 In RA synovial tissue, amphiregulin results in increased VEGF, IL-8, and IL-6 expression. Additionally, expression of EGFR has been detected in the synovial lining of patients with RA and mice with adjuvant-induced arthritis. 120 In a mouse model of RA, administration of an EGFR auto-inhibitor decreased arthritis scores. 121 While the role of EGFR has not been as extensively evaluated in OA, mice with decreased EGFR activity have a slower progression of post-traumatic OA and less cartilage damage than those with normal EGFR activity. 122 Based on the results of these studies, EGFR signaling may be important in the development and progression of arthrtitis, however, further studies are warranted.
Platelet-Derived Growth Factor Receptor
Another receptor tyrosine kinase, platelet-derived growth factor receptor (PDGFR), has PDGF as its main ligand. Several isoforms, A-D, of PDGF exist, with high expression of PDGF-B, moderate expression of PDGF-C and -D, and low expression of PDGF-A in OA and RA synoviocytes. 123 Systemic expression of PDGFR is low but is induced in a variety of tissues during inflammation. 124 An early study evaluating human synovial expression of PDGFR, determined that PDGFR was not expressed in the healthy synovium; however, expression was seen in inflamed synovial tissue. 125 In RA synovial tissue, activation of PDGFR promotes the formation of invadosomes, which are vesicles in arthritic synoviocytes that promote extracellular matrix degradation. 126 Further studies are needed to fully understand this receptor's role in inflammatory arthropathies.
Vascular Endothelial Growth Factor Receptor
Vascular endothelial growth factor receptor (VEGFR), a receptor tyrosine kinase, signals via VEGF through VEGFR1 and 2.
127 VEGF is important in angiogenesis and may play a role in inflammation. Blockade of VEGF in mice with adjuvant-induced arthritis delayed the onset of arthritis, decreased histologic evidence of synovivits and joint destruction, and decreased vascular density.
128 VEGFR1 has been detected in synovial tissue of patients with temporomandibular joint derangement, control joints, 129 in patients undergoing hip arthroplasty, 127 and in healthy rabbits and those with experimental temporomandibular trauma. 130 Although VEGF and its receptor are important in angiogenesis, the role of VEGF in OA and RA warrant further study.
Fibroblast Growth Factor Receptor
Fibroblast growth factor receptor (FGFR) is another member of the receptor tyrosine kinase inhibitor family. FGF signals through four receptor variants FGFR1-4. 131 Like VEGFR1, FGFR-1 has been detected in synovial tissue of patients with temporomandibular joint derangement, control joints, 129 in patients undergoing hip arthroplasty, 127 and in healthy rabbits and those with experimental temporomandibular trauma. 130 The effects of FGF on cartilage homeostasis are controversial, as some studies report catabolic effects, 132 while others report anabolic effects. 133 These effects have been further classified and appear to be species dependent. In mice with meniscal injury, FGF prevents progression of OA, while in human articular cartilage, FGF results in proteoglycan loss. This is suspected to be due to differential expression of FGFR subtypes, as mice primarily express FGFR2 and FGF4, which is anabolic, and catabolic FGFR1 and FGFR3 predominate in human cartilage. 134 Given the contrasting results, the role of FGFR within the synovium warrants further investigation.
Discoidin Domain Receptor 2
The final tyrosine kinase receptor evaluated in the joint is discoidin domain receptor 2, which is expressed in the synovial lining in OA tissues 135 and has a role in cartilage maintenance and pathologic destruction. 136 Further studies regarding the effects of these receptors within the synovium are warranted.
Toll Like Receptors
TLRs are a group of pattern recognition receptors that are important in the recognition of microbial components and endogenous inflammatory mediators. There are 10 types of TLRs reported in mammals, TLR1-10. 137 In synovial tissue from healthy and OA joints, TLR1-6 receptors are expressed, with TLR3 followed by TLR4 showing the highest expression, and TLR5 with extremely low expression. 138 In another study, TLR2 and TLR5 expression was identified in both OA and normal synoviocytes, with greater expression in OA tissue.
139 TLR2 and four have been detected in the synovium of dogs with OA 140 and TLR7 has been identified in the synovial lining of rats with adjuvantinduced arthritis. 141 Synovial TLR seems to play a significant role in synovial inflammation and the development of inflammatory arthropathies, as inhibition of TLR7 expression decreases cartilage damage and the production of IL-6 and IL-1b in rats. 141 Synovial TLR 2, 3, 4, 142 and 5 143 activation induces IL-6 and matrix metalloproteinase-3 release. Additionally, stimulation of TLR2 and four augment production of TNFa, IL-6, and IL-8, and may up-regulate matrix metalloproteinases-1, 2, 3, and 13. 144 Bone Morphogenetic Protein Receptors Bone morphogenetic proteins function as cytokines, growth factors, and also modulate bone metabolism. There are two types of bone morphogenetic receptors (BMPR), Type I and Type II, with several subtypes of the type I receptor, type IA, type IB, and type IA activin receptor. BMPR-1A, BMPR-1B, and BMPR-2 were detected in the synovium, 145, 146 with significantly higher expression of BMPR-1A. 146 BMPR-1A synovial expression has been negatively correlated to histologic 1594 KLEINE AND BUDSBERG grade 145 and may be important in the production and expression of extracellular matrix in articular cartilage. 147 
Adipocytokine Receptors
Adiponectin is an adipocytokine that has been shown to have insulin-sensitizing effects, 148 and may aid in artherosclerosis regulation, and the induction of inflammation. 149 With the discovery of a link between adipocytokines and inflammatory joint disease, 148 research into synovial adipokines was warranted. Adipocytokines have been identified in synovial fluid of both RA and OA patients. 150 Articular adiponectin has been linked to increased production of monocyte chemoattractant protein-1, 149 IL-6, 148,149 IL-8, 151 and PGE 2 152 by synoviocytes, and has resulted in higher concentrations of synovial fluid IL-6. 149 Adiponectin receptors 1 and 2 have been detected in synovial tissue 149, 152 from humans with RA and OA, 149 however, the function of these receptors in the synovium is not known.
Lipoprotein Receptors
Lipoproteins, transporters of triglycerides, are important in inflammation. They have been associated with the progression of OA, 153 therefore synovial lipoproteins and their receptors have been evaluated. Low-and high-density lipoprotein receptors have been discovered in RA synovium 154 but they have not been evaluated in OA tissue. By blocking the high-density lipoprotein receptor, inhibition of serum amyloid A induced IL-6 and IL-8 release occured. 155 
Lysophosphatidic Acid
Lysophosphatidic acid is an active phospholipid that is important in angiogenesis and inflammation. 156, 157 It is the ligand for six G-protein coupled receptors, LPA [1] [2] [3] [4] [5] [6] . 157, 158 Expression of LPA 1-3 156,158 and LPA 4-6 has been detected in human RA and OA synovial fibroblasts. 158 Lysophosphatidic acid binding to LPA 1 resulted in up-regulation of the expression of the adhesion molecules VCAM and ICAM. 158 LPA 1 blockade prior to induction of arthritis, results in a significant reduction in inflammation associated with adjuvant injection.
157,158
Endothelial Protein C Receptors Endothelial Protein C receptor is important in coagulation but may also enhance anti-inflammatory action. It binds with similar affinity to both protein C and activated protein C. It is important in coagulation but may also enhance anti-inflammatory activity. It is primarily expressed on endothelial cells, 159 but has been identified in the synovial lining of RA and OA tissue. 160 Its function in OA synovium is currently unknown.
Angiotensin II Receptors
Classically, angiotensin II is thought of as a regulatory enzyme involved in fluid balance and control of blood pressure, however, there is some evidence it may be involved in up-regulation of pro-inflammatory cytokines. 161 Angiotensin II is formed from angiotensin I, under the control of angiotensin converting enzyme. There are two types of angiotensin II receptors AT1R, which is responsible for a majority of the cardiovascular effects, and AT2R, which is up-regulated in inflammation, ischemia, and trauma. 162 Captopril, an angiotensin converting enzyme inhibitor, has shown therapeutic benefits in patients with RA, which led to the discovery of angiotensin converting enzyme within synovial fluid. 163 Both AT2R 162 and AT1R have been detected in rats with induced arthritis. 161, 162 Also AT1R has been identified within the RA and OA synovium, 164 however, the role in the synovium is not well studied.
Cannabinoid Receptors
The cannabinoids have received recent attention as potential analgesic drugs. There are two main types of cannabinoid receptors, CB1 and CB2, which are both G-protein coupled. 165, 166 Typically, the CB1 is more abundant in nervous tissue while CB2 is more localized in immune tissue. 47, 166, 167 Endocannabinoids have been detected in synovial tissue 165 and synovial fluid 168 from both healthy patients and those with active arthropathies. CB1 165 and CB2 169 receptors are expressed in the OA synovium. CB2 receptors have also been detected in synovial membranes of both healthy and rats with adjuvant-induced arthrits. 170 Further research into the analgesic effects of synovial cannabinoid receptors is warranted.
Estrogen Receptors
Estrogen receptors a and b are members of the steroid receptor family. 171 Due to the correlation of synovial fluid estrogen levels and arthritis severity, 171 estrogen receptors in synovial tissue were evaluated. In the synovium of healthy male rats 171, 172 and those with induced arthritis, 171 estrogen receptor a was localized within synoviocytes. 172 In human synovial tissue, both estrogen receptor a and b have been detected from healthy, RA, 173 and OA samples. 19 Estrogen administration in rats has resulted in a dose-dependent decrease in cartilage thickness and a decrease in extracellular matrix. 174 
Notch Receptors
Notch receptors are important in cell differentiation, cell homeostasis, apoptosis, 175 and chondrogenesis. 176 Mammals have four distinct Notch receptors, Notch1-4, with five ligands. The ligands, like their receptors, are trans-membrane proteins, that activate the receptor during cell-to-cell contact. 175 Notch 1 and Notch 3 receptors have been localized to the synovial lining in RA tissue. 177 Synovial Notch1 receptors have also been found in 7-day old calves 178 and Notch 1, 2, and 4 in postnatal mice. 179 While these are found in developing animals 178, 179 they do appear to have several functions in adult SYNOVIAL MEMBRANE RECEPTORS AS THERAPEUTIC TARGETS animals. In OA, inhibition of Notch signaling results in decreased proliferation of chondrocytes. Additionally, expression of insulin like growth factor 2 increased, while bone morphogenetic protein-2 and IL-8 expression were decreased. 180 Over-expression of Notch results in increased matrix metalloproteinase-13 levels and inhibition of Notch results in increased quantity of type II collagen. 181 
Relaxin Receptor
Relaxin is important in modulating ligament laxity during pregnancy and has been recently implicated as a regulator of collagen metabolism. It has been detected in the synovial lining of patients undergoing arthroplasty. 182 Despite it is synovial localization, its role in the joint is unclear.
Death Receptor A relative of the tumor necrosis factor receptor, the death receptor, is important for apoptosis and has been detected in mouse synovial tissue, after the induction of inflammation. 183 Inhibition of death receptor 3 has resulted in significantly less cartilage degradation and matrix metalloproteinase-9 levels. 183 Further studies on the role of this receptor in cartilage maintenance are warranted.
THERAPEUTIC MODULATION OF RECEPTORS IN THE SYNOVIUM Opioid Receptors
Peripheral opioids and their receptors have been shown to have anti-inflammatory effects.
11 Intra-articular administration of endorphin has resulted in decreased plasma extravasation of leukocytes and plasma proteins 184 (Table 2 ). In horses, intra-articular administration of morphine resulted in significantly decreased joint circumference, synovial amyloid A, and plasma white blood cell count compared to intravenous morphine, demonstrating a local anti-inflammatory effect. 185 Both intra-articular d-and k-receptor agonists have been associated with a decrease in bradykinininduced plasma extravasation. 186 Also, a k-specific agonist decreased myeloperoxidase activity in rats. 187 
Glucocorticoid Receptors
The therapeutic role of glucocorticoids in arthropathies has been extensively evaluated. In RA, oral prednisolone has resulted in an increase in functional activity, decrease in pain, and decreased radiographic progression of joint destruction when compared to patients on disease modifying anti-rheumatic drugs. 188, 189 In contrast, oral prednisolone has not been efficacious in the treatment of OA. 190 To limit the side effects of systemic glucocorticoids, intra-articular administration has been evaluated in humans, 191, 192 mice, 193 and horses. 95 In RA, intra-articular glucocorticoid injections are a mainstay of symptomatic treatment as they decrease synovitis, joint swelling, and discomfort. 194 In horses, intra-articular administration of triamcinolone was associated with a significant improvement in lameness. 195 Finally, intra-articular injection of triamcinolone decreased mechanical allodynia as assessed by von Frey mechanical testing in mice with meniscal injury. 193 Despite their widespread use, not all patients respond to intra-articular glucocorticoid injection. Patients with higher levels of synovial fluid VEGF concentrations and those with greater joint destruction seem to be less likely to respond to treatment with intra-articular glucocorticoids. 196 Similar to RA, intra-articular administration of corticosteroids provide pain relief and increase joint function in patients with OA 191, 197, 198 in some but not all patients. Despite improvement in pain, no improvement in ultrasound parameters of synovial inflammation has been shown after administration of intra-articular corticosteroids. 192 As glucocorticoids are important in symptomatic relief of arthropathies, there is an extensive body of literature available regarding their use, however, this is beyond the scope of this review.
Despite the analgesic benefits, disease-modifying effects of glucocorticoids in RA and OA are incompletely studied. In equine cartilage explants, the effects of methylprednisone and glycosaminoglycan synthesis were evaluated. Methyprednisone decreased glycosaminoglycan synthesis, even at low doses. 199 Similarly, high doses of prednisone resulted in chondrocyte toxicity but had no effect on glycosaminoglycans in porcine cartilage. 200 In addition to the effects on cartilage break down, glucocorticoids may result in chondrocyte apoptosis. 201 Prior to administration of intra-articular glucocorticoids, effects on the cartilage must be considered and further research into disease-modifying and chondrotoxic effects of glucocorticoids is warranted.
Glutamate Receptors
The local effects of glutamate modulating drugs have been evaluated. The NMDA antagonists, ketamine and memantine, have been associated with decreased pain and increased weight bearing in rats. 202 Intraarticular injection of inotropic glutamate receptor antagonists may decrease pain in mice, 203 while intraarticular blockade of Group I metabotropic receptors in rats resulted in a reduction in pain from inflammatory arthritis. 204 In contrast, weight bearing and pain behaviors have improved with activation of both Group II and III metabotropic glutamate receptor agonists. 205 Local blockade of synovial AMPA and kainate receptors has resulted in a decrease in meniscal IL-6 concentrations in rats.
30
Transient Receptor Potential TRPVs may be important not only in thermosensing but also in nociception. Intra-articular administration of a TRPV1 antagonist decreased pain in rats. 33, 206 Also, intra-articular injection of a TRPV4 agonist resulted in an increase in plasma extravasation, increased myeloperoxidase activity, and decreased the pain threshold. 207 
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Interleukin Receptors IL-1 and its receptors may play an early role in the development of arthritis, therefore they may represent an important therapeutic target. 208 In bovine articular cartilage explants, antagonism of the IL-1 receptor decreased glycosaminoglycan release. 209 Early intraarticular administration of anakinra, an IL-1R antagonist, after anterior cruciate ligament transection in mice has resulted in decreased cartilage degeneration and increased lubricin, a glycoprotein important for lubrication and chondroprotection. 210 After articular trauma, administration of an IL-1R antagonist reduced cartilage degeneration and synovitis severity in mice. Additionally, these findings were more pronounced when this molecule was administered intraarticularly compared to systemic administration. 211 Local treatment of arthropathies with IL-1R antagonists show promise; however, the side effects of these antagonists is yet to be determined.
Tachykinin
The neurokin 1 receptor in arthropathies may be important in analgesia and inflammation. A neurokinin 1 receptor antagonist administered intraarticularly decreased cartilage erosion and decreased mechanical 92 and thermal hyperalgesia. 212 No analgesic effects of a different neurokinin 1 antagonist were present in another study but it did decrease plasma extravasation and myeloperoxidase activity.
213
Serotonin 5-HT and it is receptors may be important in nociception, as intra-articular injection of 5-HT caused an increase in spinal neuronal excitation, specifically as it relates to nociception. 214, 215 Local injection of ketanserin, 215 and methiothepin, a 5-HT 7 antagonist, 214 both decreased spinal excitation.
Toll Like Receptors
Modulation of the TLR offers a promising modality for the treatment of arthropathies, particularly RA. Previously it has been reported that 5-HT receptor antagonists inhibit TLR 3, 7, 8, and 9, therefore the evaluation of a commonly used selective serotonin reuptake inhibitor, fluoxetine, was evaluated. In mice with adjuvant-induced arthritis, fluoxetine slowed the progression of disease. Additionally, fluoxetine reduces TLR3 induced IL-6 production in human RA synovial fibroblasts. 216 Although other systemic inhibitors of TLRs may be effective in RA, there is a concern that system TLR inhibition could lead to immunosuppression; therefore intra-articular therapies are attractive. Lubricin can also bind to TLR 2, 4, and 5 in a dose dependent manner, which results in decreased cytokine secretion in human OA synovial fibroblasts. Additionally, lubricin administered intra-articularly to mice with meniscal injury decreased synovial inflammation, cytokine expression, and pain. 139 Local TLR inhibition may represent a new target in the management of arthropathies.
Angiotensin II Receptors
Losartan, an angiotensin II receptor antagonist, has potential therapeutic benefit in inflammatory arthritis by decreasing the concentration of TNFa in rat synovium. 162 It has also been associated with a decrease VEGF concentration 162 and attenuation of the anti-apoptotic effects of angiotensin II in OA. 164 
Cannabinoids
Cannabinoids are thought to be important mediators of anti-nociception as activation of CB2, has been associated with a decrease in nociceptive fiber activity, inhibition of windup pain 217 and a decrease pain scores. 218 In chronic arthritis of rats, local administration of a CB1 agonist resulted in a decreased nociceptive fiber firing rate in response to a mechanical stimulus. 167 Adverse Effects of Intra-Articular Receptor Modulation Diarthrodial joints are well suited to intra-articular injection and the local delivery of therapeutics. Certainly there are many potential benefits including increased bioavailability, reduced systemic exposure, and decreased adverse events with drugs delivered by this method. 219 However, this method of drug administration is not completely benign. Drugs such as local anesthetics are classically known for their chondrotoxic effects. 220, 221 Additionally, the glucorticoids, particularly triamcinolone, have decreased chondrocyte viability, 220, 222 while morphine may provide a less chondrotoxic option for intra-articular analgesia. 223 The research on the cartilaginous effects of many intra-articular therapeutics is poorly understood and must be considered prior to administration of these medications. Post-injection flare, as a result of synovitis in response to injected substances, occurs in about 2-6%. 224 Infection, a rare but serious complication of arthrocentesis and intra-articular drug administration, particularly corticosteroids, has been reported in 1 in 3,000 to 1 in 50,000 patients. 224, 225 In addition to potential adverse effects of intra-articular injection, accurate placement is not always achieved, particularly for joints such as the coxofemoral joint. 226 While intra-articular delivery of therapeutic agents may offer many benefits over systemic administration, the risks associated with intra-articular drug administration must be carefully considered.
SUMMARY AND CONCLUSION
There are numerous receptors present within the synovium and articular cartilage that regulate many different functions. Based on the literature presented here there are several important receptors in the synovium that modulate nociception such as opioid, glutamate, TRPV, and cannabinoid receptors. The proinflammatory effects of TLR, histamine, interleukin, prostacyclin, EGF, and chemokine receptors is balanced by the anti-inflammatory receptors, adenosine, glucocorticoid and cholinergic. Synovial receptors, chemokine, lipoxin, TLR, death, adenosine, and prostaglandin, are important in cartilage maintenance and turnover. As some receptors, opioids, glucocorticoid, glutamate, and interleukin, have important therapeutic implications, further research into local therapeutic modulation of these receptors is crucial.
The activity of synovial membrane receptors represents a balance between cartilage degradation and repair and synovial inflammation and antiinflammatory effects. Understanding the role of synovial receptors may ultimately help to guide treatment of many arthropathies, particularly OA, by not only modulating cartilage repair and destruction but also by decreasing the pain associated with arthritis. 
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